Weight gain and insulin therapy

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 4, 2004, Pages 264-267

  Khan, Rehman ^a  

^a BASILDON HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Insulin; Insulin detemir; Limiting weight gain; Mechanisms; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; AMYLIN; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HORMONE ANALOG; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; MYRISTIC ACID; PLACEBO; PRAMLINTIDE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; MENTAL STRESS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; RISK REDUCTION; WEIGHT GAIN;

EID: 4444290077     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040040901     Document Type: Article

References (30)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140-6.
3. The DCCT Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711-21.
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(suppl 3):S18-S24.
5. Snoek FJ. Breaking the barriers to optimal glycaemic control--what physicians need to know from patients' perspectives. Int J Clin Pract Suppl 2002;(129):80-4.
6. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178-85.
7. Bryden KS, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 1999; 22:1956-60.
8. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9.
9. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700-07.
10. The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988; 11:567-73.
11. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-82.
12. Chen JW, Christiansen JS, Lauritzen T. Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab 2003;5: 223-33.
13. Heise T, Nosek L, Biilmann Rønn B et al. Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People with Type 1 Diabetes. Diabetes 2004;53:1614-20.
14. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am 1997;26:599-610.
15. Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes Metab 2000;26(suppl 30):42-5.
16. Reaven GM. Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc 1985;33(2):93-5.
17. Spiegelman BM. Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 1997;28:457-64.
18. Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29(4 Pt 2):6S36-43.
19. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 2003;29(4 Pt 2):6S71-6.
20. Johnson M, Krosnick A, Carson F, McDade AM, Laraway K. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 1998;20:691-8.
21. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003;26: 138-43.
22. Day C, Archer H, Bailey CJ. Recent advances in insulin therapy. Br J Cardiol 2003;10:379-83.
23. De Leeuw I, Selam J-L, Skeie S, Elte JWF, Lang H, Vague R. Insulin detemir-based used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diab Obes Metab 2004;in press.
24. Standl E, Roberts A, Lang H, Draeger E. Long-term efficacy and safety of insulin detemir in subjects with type 1 diabetes. Favorable weight development and risk reduction of nocturnal hypoglycemia. Diabetes 2002;51(suppl 2):A115.
25. Vague F, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.
26. Home P, Bartley F, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004;27:1081-7.
27. Russell-Jones D, Draeger E, Simpson R, Bolinder J, Hylleberg B. Effects of once-daily insulin detemir or NPH insulin on blood glucose control in people with type 1 diabetes using a basal-bolus regimen. Clin Ther 2004;26:724-36.
28. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004 [Epub ahead of print].
29. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diab Obes Metab 2004;in press.
30. Pieber TR, Plank J, Goerzer E et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 2002;51(suppl 2):A53.